Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Gideon M. Blumenthal*, Paul A. Bunn, Jamie E. Chaft, Caroline E. McCoach, Edith A. Perez, Giorgio V. Scagliotti, David P. Carbone, Hugo J. W. L. Aerts, Dara L. Aisner, Jonas Bergh, Donald A. Berry, Anthony Jarkowski, Nicholas Botwood, Darren A. E. Cross, Max Diehn, Nicole L. Drezner, Robert C. Doebele, Collin M. Blakely, Wilfried E. E. Eberhardt, Enriqueta FelipLuca Gianni, Steven P. Keller, Patrick J. Leavey, Shakun Malik, Francesco Pignatti, Tatiana M. Prowell, Mary W. Redman, Naiyer A. Rizvi, Rafael Rosell, Valerie Rusch, Dirk de Ruysscher, Lawrence H. Schwartz, Rajeshwari Sridhara, Rolf A. Stahel, Stephen Swisher, Janis M. Taube, William D. Travis, Patricia Keegan, Jacinta R. Wiens, Ignacio I. Wistuba, Murry W. Wynes, Fred R. Hirsch, Mark G. Kris

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish
Pages (from-to)1818-1831
Number of pages14
JournalJournal of Thoracic Oncology
Volume13
Issue number12
DOIs
Publication statusPublished - Dec 2018

Keywords

  • Neoadjuvant therapy
  • Induction chemotherapy
  • Resectable lung cancer
  • Pathologic response
  • Preoperative therapy
  • PATHOLOGICAL COMPLETE RESPONSE
  • POSITRON-EMISSION-TOMOGRAPHY
  • CHEMOTHERAPY PLUS SURGERY
  • CIRCULATING TUMOR-CELLS
  • 1ST FDA APPROVAL
  • PHASE-II TRIAL
  • PREOPERATIVE CHEMOTHERAPY
  • RANDOMIZED-TRIAL
  • INTERNATIONAL ASSOCIATION
  • ADJUVANT CHEMOTHERAPY

Cite this